幽门螺杆菌根除治疗对肠道微生态影响的研究进展

Advances in Study on Effects of Helicobacter pylori Eradication Therapy on Intestinal Microecology

全球约半数人群存在幽门螺杆菌(Hp)感染,目前我国Hp感染处理共识报告推荐使用由质子泵抑制剂(PPI)、铋剂联合两种抗菌药物组成的铋剂四联疗法根除Hp。然而大剂量抗菌药物和PPI口服用药易扰乱肠道菌群与宿主的正常共生状态,削弱生物屏障的保护作用,而根除治疗引起的肠道菌群组成的继发性改变又可能与根除治疗相关不良反应以及根除后感染复发有关。本文就Hp根除治疗对肠道微生态的影响以及益生菌在Hp根除治疗中作用的研究进展作一综述。

It is documented that nearly half of the global population have been infected with Helicobacter pylori （Hp）. In Chinese consensus report on management of Hp infection, bismuth quadruple therapy composed of proton pump inhibitor, bismuth and two antibiotics is recommended as the first-line Hp eradication regimen. However, large doses of oral antibiotics and PPI often disrupt the well-balanced host-microbial symbiotic state, and impair the protective effect of biological barrier. Furthermore, the alteration of microbial composition secondary to eradication therapy might be associated with the increased adverse effects of Hp eradication therapy and re-infection. This paper summarized the advances in study on effects of Hp eradication therapy on intestinal microecology and the advantages of probiotics supplementation in Hp eradication therapy.